About royalty pharma plc - RPRX
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
RPRX At a Glance
Royalty Pharma Plc
110 East 59th Street
New York, New York 10022
| Phone | 1-212-883-0200 | Revenue | 2.38B | |
| Industry | Pharmaceuticals: Major | Net Income | 770.95M | |
| Sector | Health Technology | 2025 Sales Growth | 5.064% | |
| Fiscal Year-end | 12 / 2026 | Employees | 100 | |
| View SEC Filings |
RPRX Valuation
| P/E Current | 27.265 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 21.691 |
| Price to Sales Ratio | 9.171 |
| Price to Book Ratio | 2.557 |
| Price to Cash Flow Ratio | 8.40 |
| Enterprise Value to EBITDA | 21.35 |
| Enterprise Value to Sales | 14.035 |
| Total Debt to Enterprise Value | 0.269 |
RPRX Efficiency
| Revenue/Employee | 23,781,930.00 |
| Income Per Employee | 7,709,470.00 |
| Receivables Turnover | 2.691 |
| Total Asset Turnover | 0.126 |
RPRX Liquidity
| Current Ratio | 2.402 |
| Quick Ratio | 2.402 |
| Cash Ratio | 1.002 |
RPRX Profitability
| Gross Margin | 99.838 |
| Operating Margin | 65.576 |
| Pretax Margin | 55.681 |
| Net Margin | 32.417 |
| Return on Assets | 4.074 |
| Return on Equity | 11.487 |
| Return on Total Capital | 4.992 |
| Return on Invested Capital | 5.387 |
RPRX Capital Structure
| Total Debt to Total Equity | 138.446 |
| Total Debt to Total Capital | 58.062 |
| Total Debt to Total Assets | 45.702 |
| Long-Term Debt to Equity | 132.579 |
| Long-Term Debt to Total Capital | 55.601 |